These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38896006)

  • 1. Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.
    Nouhravesh N; Garg J; Rockhold FW; De Pasquale CG; O'Meara E; Lewis GD; Butler J; Harrington J; Ezekowitz JA; Ponikowski P; Troughton RW; Wong YW; Blackman N; Numan S; Adamczyk R; Hernandez AF; Mentz RJ
    Eur J Heart Fail; 2024 Jun; ():. PubMed ID: 38896006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials.
    Rosano GM; Kalantar-Zadeh K; Jankowska EA
    ESC Heart Fail; 2023 Apr; 10(2):1294-1304. PubMed ID: 36722321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and predictors of hypophosphataemia after ferric carboxymaltose use-A 3-year experience from a single institution in Singapore.
    Chu Z; Cushway T; Wong M; Lim KX; Peh WM; Ng CT; Lim WY; Ong SGK; Tey TT; Foo FJ; Koh FH
    Br J Haematol; 2023 Sep; 202(6):1199-1204. PubMed ID: 37455143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
    Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
    Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
    Fang W; Kenny R; Rizvi QU; McMahon LP; Garg M
    BMC Gastroenterol; 2020 Jun; 20(1):183. PubMed ID: 32522150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
    Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
    Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Zoller H; Wolf M; Blumenstein I; Primas C; Lindgren S; Thomsen LL; Reinisch W; Iqbal T
    Gut; 2023 Apr; 72(4):644-653. PubMed ID: 36343979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
    Kassianides X; Bhandari S
    BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
    Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh TA; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD
    ESC Heart Fail; 2014 Sep; 1(1):52-58. PubMed ID: 28834668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose.
    Rosano G; Schiefke I; Göhring UM; Fabien V; Bonassi S; Stein J
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33172157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
    Mentz RJ; Garg J; Rockhold FW; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; She L; Harrington J; Adamczyk R; Blackman N; Hernandez AF;
    N Engl J Med; 2023 Sep; 389(11):975-986. PubMed ID: 37632463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
    Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
    Butler J; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Dorigotti F; Metra M; Piña IL; Coats AJS; Rosano G; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Anker SD; Ponikowski P
    Eur J Heart Fail; 2022 May; 24(5):821-832. PubMed ID: 35279929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Ferric Carboxymaltose Supplementation in Patients with Heart Failure with Preserved Ejection Fraction: Role of Attenuated Oxidative Stress and Improved Endothelial Function.
    Mollace A; Macrì R; Mollace R; Tavernese A; Gliozzi M; Musolino V; Carresi C; Maiuolo J; Nicita M; Caminiti R; Paone S; Barillà F; Volterrani M; Mollace V
    Nutrients; 2022 Nov; 14(23):. PubMed ID: 36501086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.
    Huang LL; Lee D; Troster SM; Kent AB; Roberts MA; Macdougall IC; McMahon LP
    Nephrol Dial Transplant; 2018 Sep; 33(9):1628-1635. PubMed ID: 29165637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.
    von Haehling S; Doehner W; Evertz R; Garfias-Veitl T; Derad C; Diek M; Karakas M; Birkemeyer R; Fillippatos G; Lainscak M; Butler J; Ponikowski P; Böhm M; Friede T; Anker SD
    Eur Heart J; 2024 Oct; 45(37):3789-3800. PubMed ID: 39185895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial.
    Del Canto I; Santas E; Cardells I; Miñana G; Palau P; Llàcer P; Fácila L; López-Vilella R; Almenar L; Bodí V; López-Lereu MP; Monmeneu JV; Sanchis J; Moratal D; Maceira AM; de la Espriella R; Chorro FJ; Bayés-Genís A; Núñez J;
    J Am Heart Assoc; 2022 Apr; 11(7):e022214. PubMed ID: 35301854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
    Martens P; Dupont M; Dauw J; Nijst P; Herbots L; Dendale P; Vandervoort P; Bruckers L; Tang WHW; Mullens W
    Eur Heart J; 2021 Dec; 42(48):4905-4914. PubMed ID: 34185066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.